Cargando…

What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study

BACKGROUND: The aim of the present study was to evaluate the efficacy and safety of intravitreal conbercept combined with trabeculectomy and panretinal photocoagulation for neovascular glaucoma (NVG). METHODS: Fifty patients (54 eyes) with NVG were included in this prospective study. Fifty-two eyes...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Liukun, Yang, Jin, Lin, Jinyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560891/
https://www.ncbi.nlm.nih.gov/pubmed/31185956
http://dx.doi.org/10.1186/s12886-019-1138-6
_version_ 1783426043757985792
author Shi, Liukun
Yang, Jin
Lin, Jinyong
author_facet Shi, Liukun
Yang, Jin
Lin, Jinyong
author_sort Shi, Liukun
collection PubMed
description BACKGROUND: The aim of the present study was to evaluate the efficacy and safety of intravitreal conbercept combined with trabeculectomy and panretinal photocoagulation for neovascular glaucoma (NVG). METHODS: Fifty patients (54 eyes) with NVG were included in this prospective study. Fifty-two eyes initially underwent intravitreal conbercept (0.5 mg/0.05 ml) treatment followed by trabeculectomy and panretinal photocoagulation. Preoperative and postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP), the number of antiglaucoma medications, and surgical complications were recorded. The levels of VEGF-A, TGF-β(1) and PLGF in aqueous humour samples collected during surgery were measured by enzyme-linked immunosorbent assay (ELISA). Light microscopy and transmission electron microscopy were used to observe the surgically excised trabecular tissue; enucleation was performed in 2 eyes, and light microscopy was used as the histopathological control. RESULTS: The follow-up period after trabeculectomy was 1 year. Of the 52 eyes, 39 completed 1 year of follow-up, and 13 were lost to follow-up. Recurrence of iris neovascularization was observed in 5 eyes, 9 had hyphema, 16 had filter-bled scarring, and no eye had complications attributable to the drug. The mean IOP was reduced from 48.1 ± 14.2 to 23.2 ± 8.7 mmHg, and the mean number of antiglaucoma medications used decreased from 3.0 (3.0, 4.0) to 1.0 (0.0, 1.0) after 1 year (both P < 0.05). The complete success rate was 76.9, 76.9, 71.0, 51.6, and 32.3% at 1 week, 1 month, 3 months, 6 months and 12 months, respectively, when the cut-off IOP was 18 mmHg. After patients underwent intravitreal injection, the concentrations of VEGF-A and TGF-β(1) in the aqueous humour in NVG patients decreased from 168.8 ± 13.4 and 159.6 ± 15.4 pg/ml to 160.2 ± 7.6 and 151.9 ± 2.3 pg/ml, respectively (both P < 0.05). Light microscopy revealed neovascularization regression in the iris in specimens treated with intravitreal conbercept. Electron microscopy revealed trabecular endothelial cell degeneration in the conbercept-treated specimens. CONCLUSIONS: Our initial findings suggest that intravitreal conbercept is an effective treatment for managing NVG that has fewer short-term postoperative complications. TRIAL REGISTRATION: Current Controlled Trials ChiCTR1800019918, 8 December 2018, retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12886-019-1138-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6560891
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65608912019-06-14 What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study Shi, Liukun Yang, Jin Lin, Jinyong BMC Ophthalmol Research Article BACKGROUND: The aim of the present study was to evaluate the efficacy and safety of intravitreal conbercept combined with trabeculectomy and panretinal photocoagulation for neovascular glaucoma (NVG). METHODS: Fifty patients (54 eyes) with NVG were included in this prospective study. Fifty-two eyes initially underwent intravitreal conbercept (0.5 mg/0.05 ml) treatment followed by trabeculectomy and panretinal photocoagulation. Preoperative and postoperative best-corrected visual acuity (BCVA), intraocular pressure (IOP), the number of antiglaucoma medications, and surgical complications were recorded. The levels of VEGF-A, TGF-β(1) and PLGF in aqueous humour samples collected during surgery were measured by enzyme-linked immunosorbent assay (ELISA). Light microscopy and transmission electron microscopy were used to observe the surgically excised trabecular tissue; enucleation was performed in 2 eyes, and light microscopy was used as the histopathological control. RESULTS: The follow-up period after trabeculectomy was 1 year. Of the 52 eyes, 39 completed 1 year of follow-up, and 13 were lost to follow-up. Recurrence of iris neovascularization was observed in 5 eyes, 9 had hyphema, 16 had filter-bled scarring, and no eye had complications attributable to the drug. The mean IOP was reduced from 48.1 ± 14.2 to 23.2 ± 8.7 mmHg, and the mean number of antiglaucoma medications used decreased from 3.0 (3.0, 4.0) to 1.0 (0.0, 1.0) after 1 year (both P < 0.05). The complete success rate was 76.9, 76.9, 71.0, 51.6, and 32.3% at 1 week, 1 month, 3 months, 6 months and 12 months, respectively, when the cut-off IOP was 18 mmHg. After patients underwent intravitreal injection, the concentrations of VEGF-A and TGF-β(1) in the aqueous humour in NVG patients decreased from 168.8 ± 13.4 and 159.6 ± 15.4 pg/ml to 160.2 ± 7.6 and 151.9 ± 2.3 pg/ml, respectively (both P < 0.05). Light microscopy revealed neovascularization regression in the iris in specimens treated with intravitreal conbercept. Electron microscopy revealed trabecular endothelial cell degeneration in the conbercept-treated specimens. CONCLUSIONS: Our initial findings suggest that intravitreal conbercept is an effective treatment for managing NVG that has fewer short-term postoperative complications. TRIAL REGISTRATION: Current Controlled Trials ChiCTR1800019918, 8 December 2018, retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12886-019-1138-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-11 /pmc/articles/PMC6560891/ /pubmed/31185956 http://dx.doi.org/10.1186/s12886-019-1138-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Shi, Liukun
Yang, Jin
Lin, Jinyong
What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
title What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
title_full What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
title_fullStr What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
title_full_unstemmed What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
title_short What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
title_sort what is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560891/
https://www.ncbi.nlm.nih.gov/pubmed/31185956
http://dx.doi.org/10.1186/s12886-019-1138-6
work_keys_str_mv AT shiliukun whatistheimpactofintravitrealinjectionofconberceptonneovascularglaucomapatientsaprospectiveinterventionalcaseseriesstudy
AT yangjin whatistheimpactofintravitrealinjectionofconberceptonneovascularglaucomapatientsaprospectiveinterventionalcaseseriesstudy
AT linjinyong whatistheimpactofintravitrealinjectionofconberceptonneovascularglaucomapatientsaprospectiveinterventionalcaseseriesstudy